IRulya Therapeutics Inc. Common Stock
IRLA
98 hedge funds and large institutions have $243M invested in IRulya Therapeutics Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 21 reducing their positions, and 52 closing their positions.
76% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 21
31% more call options, than puts
Call options by funds: $20.8M | Put options by funds: $15.9M
0.26% less ownership
Funds ownership: 64.65% → 64.39% (-0.26%)
22% less funds holding
Funds holding: 126 → 98 (-28)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 52
86% less capital invested
Capital invested by funds: $1.76B → $243M (-$1.52B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$30.3M |
| 2 |
Millennium Management
New York
|
+$17.1M |
| 3 |
Two Sigma Investments
New York
|
+$16M |
| 4 |
Two Sigma Advisers
New York
|
+$14.6M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$212M |
| 2 |
Capital International Investors
Los Angeles,
California
|
-$46.2M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$30.1M |
| 4 |
State Street
Boston,
Massachusetts
|
-$13.5M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.56M |
IRLA Hedge Fund Activity: Q4 2021 in Review
98 of the 6,520 institutional investors tracked by Wall St. Rank reported a position in IRulya Therapeutics Inc. Common Stock (IRLA) for Q4 2021, worth a combined $243M — down 86% from $1.76B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of IRLA and 25 opened new positions — a net loss of 27 holders — while 21 trimmed existing stakes and 37 added.
The largest buyer was Morgan Stanley, adding an estimated $30.3M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $212M sold.
- 98 institutional investors held IRulya Therapeutics Inc. Common Stock (IRLA) as of Q4 2021, down from 126 in Q3 2021.
- Funds reported $243M of IRulya Therapeutics Inc. Common Stock stock for Q4 2021, down 86% quarter-over-quarter.
- 25 funds opened new IRulya Therapeutics Inc. Common Stock positions in Q4 2021 and 52 closed out, a net change of -27 holders.
- The largest IRulya Therapeutics Inc. Common Stock buyer in Q4 2021 was Morgan Stanley, an estimated $30.3M added.
- The largest IRulya Therapeutics Inc. Common Stock seller in Q4 2021 was Capital Research Global Investors, an estimated $212M sold.
Based on aggregated 13F filings for Q4 2021.